Clinical Trial Update: A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating CLE-100, an oral esketamine, as an adjunct to a standard antidepressant for adults with major depressive disorder has completed and p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• CLE-100 (esketamine)

Snippet

Sponsor: Clexio Biosciences Ltd. | Conditions: Adjunctive Treatment of Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2025-09-24